Verastem to present RAMP 201 analyses at IGCS 2026
Verastem Oncology said new RAMP 201 molecular profiling and external control arm analyses on avutometinib plus defactinib in recurrent low-grade serous ovarian cancer will be presented at IGCS 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Verastem Oncology to Present Data from RAMP 201 Trial at IGCS 2026
Verastem Oncology announced that new molecular profiling and tumor biomarker analyses from its Phase 2 RAMP 201 clinical trial of avutometinib plus defactinib in recurrent low-grade serous ovarian cancer will be presented at IGCS 2026.